Comparative Pharmacology
Head-to-head clinical analysis: CEFAZOLIN AND DEXTROSE versus MANDOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFAZOLIN AND DEXTROSE versus MANDOL.
CEFAZOLIN AND DEXTROSE vs MANDOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal agent inhibiting bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis. Dextrose provides osmotic diuresis and energy source.
Cephalosporin antibiotic; inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
1-2 g IV/IM every 8 hours; maximum 12 g/day.
1-2 g IV or IM every 4-8 hours; maximum 12 g/day.
None Documented
None Documented
1.8 hours (prolonged to 20-40 hours in severe renal impairment, CrCl <10 mL/min)
Clinical Note
moderateCefamandole + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefamandole."
Clinical Note
moderateCefamandole + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefamandole."
Clinical Note
moderateWarfarin + Cefamandole
"Warfarin may increase the anticoagulant activities of Cefamandole."
Clinical Note
moderatePhenprocoumon + Cefamandole
Terminal elimination half-life is 1.2-1.8 hours in adults with normal renal function; prolonged to 4-8 hours in moderate renal impairment (CrCl 30-50 mL/min) and >12 hours in severe impairment (CrCl <30 mL/min).
Renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal (<5%)
Renal: 65-85% unchanged via glomerular filtration and tubular secretion; biliary/fecal: ~15-20% as active drug and metabolites; minor hepatic metabolism.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"Phenprocoumon may increase the anticoagulant activities of Cefamandole."